ipilimumab,nivolumab
bms
['checkmate 914', 'nivo', 'check,mate,914', 'rcc,(-irccs),(-srcc),(-urcc)', 'ipilimumab', 'nivolumab', 'renal,(-adrenal)']
adjuvant nivolumab plus ipilimumab (nivo+ipi) vs placebo (pbo) for localized renal cell carcinoma (rcc) at high risk of relapse after nephrectomy: results from the randomized, phase iii checkmate 914 trial #esmo2022 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis